

**Literaturverzeichnis zum Titelthema „Neues aus der Rheumatologie“
Bayerisches Ärzteblatt 9/2010, Seite 424 ff.
Professor Dr. Hans-Peter Tony und Dr. Martin Feuchtenberger**

1. Aletaha, D., et al., *Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment*. Arthritis Rheum, 2009. **60**(5): p. 1242-9.
2. Gorter, S.L., et al., *Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis*. Ann Rheum Dis, 2010. **69**(6): p. 1010-4.
3. Smolen, J.S., et al., *EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs*. Ann Rheum Dis, 2010. **69**(6): p. 964-75.
4. Visser, K., et al., *A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study*. Ann Rheum Dis, 2010.
5. Ziegler, S., et al., *Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997-2007: results from the National Database of the German Collaborative Arthritis Centres*. Ann Rheum Dis, 2010.
6. Listing, J., et al., *Infections in patients with rheumatoid arthritis treated with biologic agents*. Arthritis Rheum, 2005. **52**(11): p. 3403-12.
7. IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS, SMOKING IS ASSOCIATED WITH NON-RESPONSE TO METHOTREXATE AND TNF ANTAGONISTS
S. Saevarsdottir, S. Wedrén, M. Seddighzadeh, A. Wesley, C. Bengtsson, S. Lindblad, L. Padyukov, J. Askling, L. Alfredsson, L. Klareskog.
Ann Rheum Dis 2010;69(Suppl3):55
8. Tektonidou, M.G., et al., *Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies*. Arthritis Rheum, 2009. **61**(1): p. 29-36.
9. Jones, R.B., M. Walsh, and K.G. Smith, *What is the value of mycophenolate mofetil as induction and maintenance therapy in lupus nephritis?* Curr Opin Rheumatol, 2009. **21**(3): p. 256-61.
10. Terrier, B., et al., *Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French AIR registry*. Arthritis Rheum, 2010.
11. Devauchelle-Pensec, V., et al., *Gene expression profile in the salivary gland of primary Sjogren syndrome patients, before and after treatment with Rituximab*. Arthritis Rheum, 2010.
12. Perosa, F., et al., *CD20-depleting therapy in autoimmune diseases: from basic research to the clinic*. J Intern Med, 2010. **267**(3): p. 260-77.
13. E. Molloy, L.C., *Progressive multifokal encephalopathy (PML) and biologic therapy in rheumatic diseases: an analysis of the FDA AERS database* Ann Rheum Dis, 2010. **69**(Suppl3).
14. Morganroth, P.A., M.E. Kreider, and V.P. Werth, *Mycophenolate mofetil for interstitial lung disease in dermatomyositis*. Arthritis Care Res (Hoboken), 2010.
15. Bosentan for digital ulcers in patients with systemic sclerosis: a prospective 3-year followup study. Tsifetaki N, Botzoris V, Alamanos Y, Argyriou E, Zioga A, Drosos AA. J Rheumatol. 2009 Jul;36(7):1550-2.
Bosentan: a review of its use in the management of digital ulcers associated with systemic sclerosis. Dhillion S. Drugs. 2009 Oct 1;69(14):2005-24. Review.
16. Sieper, J., et al., *The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis*. Ann Rheum Dis, 2009. **68** Suppl 2: p. ii1-44.

17. van der Heijde DMF, W.A., Spoorenberg A, van der Linden S, Dougados M, van der Tempel H, *Structural damage assessed on radiographs in patients with ankylosing spondylitis steadily increases over time*. Arthritis Rheum, 2003. **48(suppl)**: p. 175.
18. de Groot, K., et al., *Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial*. Ann Intern Med, 2009. **150**(10): p. 670-80.
19. Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis. Jones RB, Cohen Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR; the European Vasculitis Study Group. N Engl J Med. 2010 Jul 15;363(3):211-220.
20. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; the RAVE-ITN Research Group. N Engl J Med. 2010 Jul 15;363(3):221-232.
21. Fahy, W.A., et al., *Pneumococcal and influenza vaccination in patients with rheumatic conditions and receiving DMARD therapy*. Rheumatology (Oxford), 2006. **45**(7): p. 912-3.
22. Gelinck, L.B., et al., *The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination*. Ann Rheum Dis, 2008. **67**(5): p. 713-6.
23. Holvast, B., et al., *Influenza vaccination in systemic lupus erythematosus: safe and protective?* Autoimmun Rev, 2007. **6**(5): p. 300-5.
24. Kavanaugh, A., *Infection prophylaxis in antirheumatic therapy: emphasis on vaccination*. Curr Opin Rheumatol, 2009. **21**(4): p. 419-24.
25. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis & Rheumatism 2010;62:2569-81.
26. Rudwaleit, M., J. Braun, and J. Sieper, *[ASAS classification criteria for axial spondyloarthritis]*. Z Rheumatol, 2009. **68**(7): p. 591-3.